Evommune is focused on discovering and developing novel therapies designed to treat and halt the progression of chronic inflammatory disease.

Evommune

Evommune | 2,818 followers on LinkedIn. Inventing ways to treat inflammatory diseases, developing therapies that address symptoms and halt progressive disease. | Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.

Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease.

Evommune is different.

Emily Ip

Luis Peña

Research and Development Leader

Jeegar Patel, Ph.D.

Driven corporate development and strategy leader

Lauren Krusius

Thanks to Nasdaq for highlighting our Series C financing and to our mission to do something about chronic inflammation. #biotech #biotechnology #lifescience

Today, we announced the closing of a $115 million Series C financing co-led by new investors RA Capital Management and Sectoral Asset Management , with participation from additional new plus existing investors. We also welcomed Derek DiRocco , PhD and François Beaubien , Ph.D. to our Board of Directors. Proceeds will be used to support the advancement of our lead clinical programs in chronic urticaria and atopic dermatitis. Learn more: https://lnkd.in/gzjbRSUA #immunology #inflammation #urticaria #biotechnology

Thanks to New York Stock Exchange #NYSE for recognizing our $115 million Series C financing. #biotech #lifescience #biotechnology

Check out CURE article on Evommune's goal in developing new and improved treatment options for patients living with chronic inflammatory diseases. #inflammation #inflammatorydiseases #biotechnology https://lnkd.in/gNpdSaHG

Evommune wishes to congratulate Eli Lilly on obtaining FDA approval for Ebglyss™ (lebrikizumab-ibkz). Several of our current Evommune colleagues played a role in its development, and are proud of its approval. Our drive to continue to deliver meaningful new medicines to patients has never been stronger. Chronic inflammation destroys lives and Evommune is here to do something about it! https://lnkd.in/gzKkPXi7

All of us at Evommune are deeply saddened by the recent passing of Dr. Marcus Maurer, a scientific collaborator at the Institute of Allergology at Charité in Berlin. #dermatology #inflammation #immunology

Evommune will be presenting a corporate update, including this week’s news on the commencement of a Phase 2 trial in adult patients with chronic inducible urticaria, at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York City. Presentation will take place on Thursday, September 5th at the Marriott Marquis.

Dermatology Times article on our Phase 2 trial in Chronic Inducible Urticaria. https://lnkd.in/gJHp65QE

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

events

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Nov 7, 2024 8:44 AM	16bec629
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general	Nov 7, 2024 8:44 AM	c0837c36
news processing advanced	general
crunchbase trigger	general	Nov 7, 2024 8:44 AM	07de4e64
crunchbase profile	general
li profile	general	Nov 7, 2024 8:44 AM	96aa7bc0
translate crunchbase fundingrounds	general
peers	general	Nov 7, 2024 8:44 AM	de602fa2
news basic	general	Nov 7, 2024 8:44 AM	2fd017ee
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis	Nov 7, 2024 8:44 AM	dbb378c6
company structure	company_analysis
purchaser profile	merger_acquisitions
financials download nd	financials
private financials	financials
customer profile	customers

EVOM

COM:EVOMMUNE

Evommune